The scale of the analysis is what sets the work apart. Single-cell RNA sequencing allows researchers to read the gene-expression fingerprint of thousands of individual cells, but combining datasets across laboratories, species of injury models and disease states is a formidable computational challenge. The team integrated, clustered and annotated the full complement of 236,748 fibroblasts, then applied a battery of analytical tools: differential gene-expression testing to compare healthy and fibrotic states, RNA velocity to infer the direction of cellular transitions, and non-negative matrix factorization, or NMF, to decompose the transcriptional landscape into coherent gene-expression programs that recur across cells and samples.

The clustering revealed eight major populations of cardiac fibroblasts, which the researchers organized into two broad lineages. One lineage, which they termed the steady-state lineage, corresponds to the fibroblasts that maintain the structural scaffolding of the healthy heart. The second, the fibrotic-state lineage, encompasses the activated cells that expand after injury and drive pathological remodeling. This two-lineage framework gives the field a vocabulary for what has been a confusing picture: fibroblasts in a scarred heart are not simply more numerous versions of their healthy counterparts, but a collection of distinct cell states with different gene-expression signatures and, presumably, different functions.

The NMF analysis added a second layer of insight by identifying twelve meta-programs, recurring modules of co-expressed genes that cut across individual cell clusters. Among these, one connection stood out: a strong association between PDK4-mediated glycolysis and extracellular matrix deposition. PDK4, pyruvate dehydrogenase kinase 4, is an enzyme that sits at a critical metabolic junction. By phosphorylating and inhibiting the pyruvate dehydrogenase complex, it blocks the flow of pyruvate into the mitochondria and the tricarboxylic acid cycle, pushing cells toward glycolysis and the conversion of pyruvate into lactate. The finding that this metabolic program tracks with matrix production in fibroblasts suggested, provocatively, that scarring might be fueled by a specific metabolic rewiring rather than being an incidental byproduct of inflammation.

To test that idea, the researchers turned to neonatal mouse primary cardiac fibroblasts grown in the laboratory, and deployed a series of mechanistic experiments: immunoblotting to measure protein levels, metabolomics to profile metabolic intermediates, co-immunoprecipitation to detect protein interactions, and ChIP-qPCR to examine binding to chromatin. The results traced a complete signaling chain. PDK4 activity promoted the production of lactate, the metabolic end-product that accumulates when cells rely heavily on glycolysis. That lactate, in turn, drove histone H3 lactylation, a chemical modification in which lactate-derived lactyl groups are attached to histone proteins, the spools around which DNA is wound.

Histone lactylation is a relatively recent addition to the catalog of epigenetic marks, first described as a link between cellular metabolism and gene regulation. By modifying histones, lactate does not merely accumulate as waste; it can actively reshape which genes are accessible for transcription. In the fibroblasts studied here, histone H3 lactylation increased the expression of TGF-β1, transforming growth factor beta 1, the canonical profibrotic cytokine that activates fibroblasts and stimulates them to synthesize collagen and other extracellular matrix components. The chain from PDK4 to glycolysis to lactate to histone lactylation to TGF-β1 to matrix synthesis therefore constitutes a coherent mechanistic model in which a metabolic enzyme acts upstream of the central molecular driver of fibrosis.

The critical question, of course, is whether interrupting this chain in a living animal can protect the heart. The researchers addressed this in a mouse model of myocardial infarction, in which the left anterior descending coronary artery is ligated to reproduce the ischemic injury of a human heart attack. Using immunofluorescence, flow cytometry and echocardiography, they evaluated what happened when PDK4 was inhibited. The outcome was striking: blocking PDK4 alleviated cardiac fibrosis and improved cardiac function in the infarcted mice. The team also demonstrated antifibrotic effects from fibroblast-targeted PDK4 knockdown delivered by AAV9, an adeno-associated viral vector commonly used to shuttle genetic payloads into cardiac tissue, which strengthens the case that the benefit arises from acting on fibroblasts specifically rather than through indirect effects on other cell types.

These findings arrive at a moment when the metabolic control of immune and stromal cells is one of the fastest-moving areas of biology. The idea that lactate is not a dead-end metabolite but a signaling molecule capable of reprogramming gene expression has transformed how researchers think about tumors, inflammation and now fibrosis. The new study extends that framework to the heart and, importantly, connects it to a druggable target. Kinases such as PDK4 are among the most tractable enzyme classes for pharmacological inhibition, and the demonstration that PDK4 inhibition improves cardiac function after infarction in mice provides a concrete proof of concept for a therapeutic strategy that would not merely slow scarring but intervene at its metabolic source.

The single-cell atlas itself is likely to prove as valuable as the mechanistic discovery. With eight fibroblast populations, two lineages and twelve meta-programs catalogued across healthy and diseased hearts, the resource gives investigators a reference against which future studies can map their own data, identify which fibroblast states expand in particular disease contexts and design experiments that target specific subpopulations rather than fibroblasts in general. The heterogeneity that once frustrated mechanistic understanding becomes, in this framing, a map of opportunities: if only a subset of fibroblast states drives pathological matrix deposition, therapies can be aimed at those states while sparing the cells that maintain normal cardiac architecture.

Cautions remain, as they always do in translational research. The mechanistic experiments were performed largely in neonatal mouse fibroblasts and mouse models of infarction, and human cardiac fibrosis involves additional layers of comorbidity, age and medication exposure that animal models only approximate. The published version of the paper was still subject to final editorial processing at the time of its early release, and the field will want to see the findings replicated independently. Nevertheless, the study delivers something rare: a large-scale descriptive atlas, a specific molecular mechanism and an in vivo therapeutic validation, all pointing at the same target. If PDK4-driven lactylation of histones proves as central to human cardiac fibrosis as it appears to be in the mouse, the enzyme that once seemed an obscure regulator of mitochondrial fuel choice may become one of the most closely watched targets in cardiovascular medicine.

Subject of Research: Fibroblast heterogeneity and PDK4-driven metabolic activation in cardiac fibrosis after myocardial infarction

Article Title: Single-cell transcriptomics landscape decodes cardiac fibroblast heterogeneity and reveals PDK4-driven profibrotic activation during cardiac fibrosis

Article References: Qi, X., Guo, S., Sun, Y., Zhang, L., Lu, K., Huang, X., Tang, R., Zhang, N., Yu, D., & Lian, F. (2026). Single-cell transcriptomics landscape decodes cardiac fibroblast heterogeneity and reveals PDK4-driven profibrotic activation during cardiac fibrosis. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08985-3

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08985-3

Keywords: cardiac fibroblasts, single-cell transcriptomics, myocardial fibrosis, PDK4, histone lactylation, lactate, TGF-β1, extracellular matrix, myocardial infarction, glycolysis, AAV9, non-negative matrix factorization

The research team, working with mouse models spanning young adults to very old animals, first documented that aging is accompanied by an increase in CaMKII abundance. In the tibialis anterior muscles of 33-month-old mice, total CaMKIIβ and CaMKIIδ/γ protein levels were significantly elevated compared with 3.7-month-old controls, and so were the T287 autophosphorylation signals that serve as a biochemical marker of kinase activation. These aged animals also showed the expected reductions in normalized muscle mass across the tibialis anterior, gastrocnemius, and quadriceps. The authors were careful to note, however, that steady-state autophosphorylation may not fully capture chronic CaMKII signaling, because the kinase is also regulated by calcium/calmodulin binding, oxidation, nitrosylation, and O-GlcNAcylation. That ambiguity set the stage for a more direct experimental question: is sustained CaMKII activation sufficient to drive muscle dysfunction on its own?

To answer it, the researchers used adeno-associated virus serotype 9 to deliver a constitutively active form of CaMKIIγ, carrying a phosphomimetic T287D mutation, into the tibialis anterior muscles of young mice under a muscle-specific promoter. Each animal received the active kinase in one leg and a green fluorescent protein control in the other, allowing paired comparisons within the same mouse. The construct expressed at levels comparable to endogenous CaMKII, and although the transgene triggered a feedback reduction in endogenous CaMKII abundance and autophosphorylation, kinase assays and a fluorescent CaMKII activity reporter called CaMKAR confirmed that net enzymatic activity was clearly elevated in the injected muscles.

The functional consequences were striking. Six weeks after gene transfer, muscles expressing the constitutively active kinase produced significantly less force than their paired controls across the entire 1–150 Hz stimulation range, and the deficit persisted even after normalizing force to muscle mass. Mediation analysis showed that the early loss of contractile strength was almost entirely a direct effect of CaMKII signaling rather than a byproduct of the modest 7 percent reduction in muscle mass that had developed by seven weeks. In other words, the muscle was genuinely weaker, not merely smaller. Only with much longer activation did atrophy become a dominant factor: nine months after injection, muscle mass had fallen by 24.2 percent, and mediation analysis then attributed the bulk of the force decline to the loss of tissue itself.

Under the microscope, the CaMKII-activated muscles revealed a distinctive pattern of structural remodeling. There was no inflammation or necrosis, but affected fibers showed abnormal basophilic staining, intensified subsarcolemmal and intrafiber signals on modified Gomori’s trichrome staining, and aggregated mitochondrial enzymatic activity on cytochrome c oxidase and succinate dehydrogenase stains. Electron microscopy made the picture explicit: mitochondria clumped beneath the sarcolemma and between myofibrils, and a quantitative Z-line mitochondrial occupancy score dropped significantly at both seven weeks and five months. Importantly, this was a problem of geography rather than quantity. Respiratory chain subunit abundance and the mitochondrial-to-nuclear DNA ratio were unchanged, indicating that sustained CaMKII signaling scatters mitochondria away from their normal posts near the calcium release units and Z-lines without depleting them.

That mislocalization matters because intermyofibrillar mitochondria in adult muscle are normally positioned to deliver ATP locally for cross-bridge cycling and calcium reuptake, and to take up calcium during activity in a process known as excitation–metabolism coupling. Aging is known to disrupt precisely this arrangement, reducing the apposition between calcium release units and mitochondria in both aged mouse and human muscle. The authors propose that CaMKII-driven disruption of cytoskeletal anchoring, possibly through phosphorylation of desmin and related intermediate filament proteins, or altered mitochondrial dynamics via the fission regulator Drp1, could explain how a calcium-activated kinase ends up scrambling the muscle’s power grid.

The transcriptional evidence was equally compelling. RNA sequencing of young muscles expressing active CaMKII for seven weeks revealed 2,771 differentially expressed genes, and when these changes were correlated with the gene-expression signature of normal aging, the concordance was moderate but highly significant. Of the genes altered with age, 73.5 percent were shifted in the same direction by sustained CaMKII activation. Gene set enrichment analysis against the Reactome database showed that CaMKII activation in young muscle reproduced the aging-associated activation of immune, interferon-gamma, antigen-presentation, DNA-repair, and extracellular-matrix pathways, while suppressing metabolic and structural-remodeling programs. Sustained CaMKII signaling, in effect, pushed the young transcriptome toward an aged profile, though not a complete one, implying that additional pathways cooperate with CaMKII in the full aging program.

Two intervention experiments then tested causality from the opposite direction. When aged mice received AAV9-delivered CN19o, a well-characterized CaMKII inhibitory peptide, their tibialis anterior muscles generated significantly greater absolute force and significantly higher force normalized to muscle mass after five weeks, without any increase in muscle size or fiber diameter. A second cohort using phosphate-buffered saline controls confirmed the effect. Meanwhile, co-expression of a degradation-resistant IκBα super-repressor, which blocks canonical NF-κB signaling, did not prevent the early CaMKII-induced force deficit but partially preserved long-term force at ten months, independently of muscle mass. This places inflammatory NF-κB signaling downstream of CaMKII as one contributor to progressive decline, while pointing to other mechanisms for the acute weakness.

Among those other mechanisms, mediation analysis of matched transcriptomic and force data singled out heme metabolism as the principal transcriptomic correlate of CaMKII-induced weakness. Active CaMKII upregulated genes involved in heme and iron export, including Flvcr1, Abcg2, and the iron exporter Slc40a1, while downregulating genes supporting heme synthesis and iron uptake, such as Fech, Abcb10, Tfrc, and Fth1. Regulatory network inference identified the heme-responsive transcription factor Spic as the top activated factor in CaMKII-expressing young muscle and the top suppressed factor in CN19o-treated aged muscle, a reciprocal pattern consistent with dysregulated heme and iron handling. The authors suggest a model of functional iron deficiency coexisting with labile-iron accumulation, a state that could compromise mitochondrial metabolism and elevate oxidative stress, and one that echoes iron dyshomeostasis previously reported in aging human muscle.

The broader conceptual payoff is an example of what evolutionary biologists call antagonistic pleiotropy: a pathway that is adaptive in youth becomes harmful in old age. Transient CaMKII activation scales with physiological demand and resolves during recovery, supporting performance and exercise adaptation. With aging, declining functional capacity may make everyday activity a relatively greater stress, promoting more persistent CaMKII activation and shifting its effects toward dysfunction. Exercise, on this view, protects muscle not only by inducing beneficial adaptation but also by preserving the functional reserve that keeps chronic homeostatic stress in check. For people who cannot exercise enough, the findings raise the possibility of pharmacological CaMKII inhibition as a complementary strategy, a prospect sharpened by the recent identification of the FDA-approved JAK inhibitor ruxolitinib as a potent CaMKII inhibitor at therapeutic concentrations. The authors caution that their constitutively active kinase model does not perfectly reproduce the magnitude, duration, or isoform composition of endogenous CaMKII dysregulation, and that the relevance to human muscle aging remains to be established. Still, by connecting a self-amplifying calcium signal to mitochondrial mislocalization, an aged transcriptome, heme-iron disruption, and measurable weakness, the study gives sarcopenia research a concrete, druggable molecular thread to pull.

Subject of Research: The role of sustained CaMKII signaling in age-related skeletal muscle contractile dysfunction and sarcopenia

Article Title: Sustained Activation of CaMKII Promotes Skeletal Muscle Contractile Dysfunction in Aging

Article References: Bene, M. R., Chung, T., Luczak, E. D., Lopez‐Cecetaite, G., Fountain, W. A., Rosales‐Soto, G., Hernández‐Ochoa, E., Antonescu, C., Florea, L., Jeong, S. J., Elassal, E., Le, A., Xue, Q.-L., Hoke, A., Abadir, P. M., & Wang, Q. (2026). Sustained Activation of CaMKII Promotes Skeletal Muscle Contractile Dysfunction in Aging. Aging Cell, 25(9), Article e70704. https://doi.org/10.1111/acel.70704

Image Credits: AI Generated

DOI: 10.1111/acel.70704

Keywords: CaMKII, sarcopenia, skeletal muscle, aging, mitochondria, calcium signaling, NF-kB, heme metabolism, gene expression, AAV9, CN19o, contractile dysfunction